Company: SHPH
Filing Date: 2025-04-21
Form Type: DEFR14A
Source: 0001641172-25-005474
Chunk: 24

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-04-21
Form: DEFR14A
Chunk 24
---
 and PAL Trust.                                                                                                                       |
| (3) | Does                                                                                                                                 
 not include 28,455 RSUs that remain subject to vesting.                                                                              |
| (4) | Does                                                                                                                                 
 not include 1,194 RSUs that remain subject to vesting.                                                                               |
| (5) | Does                                                                                                                                 
 not include 209,791 RSUs that remain subject to vesting.                                                                             |
| (6) | Does                                                                                                                                 
 not include 184,162 RSUs that remain subject to vesting.                                                                             |

| 18 |

Related Party Transactions

Unless described below, during the last two fiscal years, there were no transactions or series of similar transactions to which we were a party or will be a party, in which:

| ● | the                                                                                                                                
 amounts involved exceed or will exceed $120,000; and                                                                               |
| ● | any                                                                                                                                
 of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of any 
 of the foregoing had, or will have, a direct or indirect material interest.                                                        |

On December 1, 2020, the Company consolidated two loans obtained in 2018 for a total of $350,000 from Joy Dritschilo, the wife of our then Chief Executive Officer, which loans accrued interest at 7.5% since the date of inception, into a single loan between Mrs. Dritschilo and the Company (the “2018 Consolidated Loan”) such that, with accrued interest, the 2018 Consolidated Loan had a principal balance of $424,005.65, bore interest at a rate of 7.5% per annum, and had a maturity date of December 31, 2021. The 2018 Consolidated Loan was then extended until June 30, 2022, pursuant to an amendment to the 2018 Consolidated Loan agreement dated January 24, 2022. On July 29, 2022, the Company and Mrs. Dritschilo entered into an amendment to the 2018 Consolidated Loan, pursuant to which repayment was extended through June 30, 2023. On January 15, 2023, following closing on the Convertible Note and Warrant offering to Ayrton Capital, the 2018 Consolidated Loan was paid off in full.

On December 1, 2020, the Company consolidated the May 2018 Loan and the September 2019 Loan with our